Hydroxychloroquine for genetic lung disease in children
Treatments studied
Part of Lungs & breathing clinical trials.
This early-phase trial studies whether hydroxychloroquine can help children with certain genetic causes of interstitial lung disease (lung scarring/inflammation). It is designed for kids who are currently stable and have not recently taken hydroxychloroquine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 18 years old and has a diagnosis of childhood interstitial lung disease (lung scarring/inflammation).
- The lung disease is confirmed to be from a genetic cause, such as genes like SFTPC, SFTPB, ABCA3, NKX2-1, or others listed in the study.
- Your child’s condition is clinically stable, with no major changes to lung or other medicines in the past 4 weeks.
- Your child has not taken hydroxychloroquine (HCQ) in the past 12 weeks.
- No severe current infection flare-ups, and no known allergy to hydroxychloroquine or the tablet ingredients.
- Your child’s kidney function is not too low for the study (based on a GFR test), and they are not in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of three drugs (azithromycin, hydroxychloroquine, and prednisone) can help people with a genetic form of lung scarring. The goal is to see if these medicines calm the immune system and slow down the disease.
This trial tests a new type of eye test (ERG) to detect early damage from hydroxychloroquine, a drug used for conditions like lupus and rheumatoid arthritis. If you take hydroxychloroquine or have never taken it, you might help find better ways to protect your vision.
This study tests whether hydroxychloroquine can slow the progression of Parkinson's disease. It is for people who have been diagnosed with Parkinson's within the last 4 years and are not yet in advanced stages.
This trial tests if hydroxychloroquine, a medicine used for other conditions, can reduce liver inflammation in people with fatty liver disease. It aims to help those whose fatty liver has caused ongoing liver damage.
This study uses special eye scans to look for early signs of damage in people who have been taking hydroxychloroquine for at least a year. It aims to help doctors monitor eye health more closely during treatment.
This study looks at how Plaquenil (hydroxychloroquine) can harm the retina (the eye’s light-sensing layer) and whether genetics affect who gets affected. You may help by sharing medical details and providing an eye-related blood sample so researchers can compare gene patterns to eye findings.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.